Department of Molecular Cell Biology and Immunology, VU University Medical Center, Amsterdam, Netherlands.
Nat Rev Immunol. 2018 Mar;18(3):204-211. doi: 10.1038/nri.2018.3. Epub 2018 Feb 5.
Tumour growth is accompanied by tumour evasion of the immune system, a process that is facilitated by immune checkpoint molecules such as programmed cell death protein 1 (PD1). However, the role of tumour glycosylation in immune evasion has mostly been overlooked, despite the fact that aberrant tumour glycosylation alters how the immune system perceives the tumour and can also induce immunosuppressive signalling through glycan-binding receptors. As such, specific glycan signatures found on tumour cells can be considered as a novel type of immune checkpoint. In parallel, glycosylation of tumour proteins generates neo-antigens that can serve as targets for tumour-specific T cells. In this Opinion article, we highlight how the tumour 'glyco-code' modifies immunity and suggest that targeting glycans could offer new therapeutic opportunities.
肿瘤生长伴随着肿瘤对免疫系统的逃逸，这一过程是由免疫检查点分子如程序性细胞死亡蛋白 1（PD1）等促进的。然而，尽管肿瘤糖基化改变了免疫系统对肿瘤的感知方式，并通过糖基结合受体诱导免疫抑制信号，但其在免疫逃逸中的作用在很大程度上被忽视了。因此，肿瘤细胞上存在的特定糖基特征可以被视为一种新型的免疫检查点。与此同时，肿瘤蛋白的糖基化产生了新的抗原，可以作为肿瘤特异性 T 细胞的靶标。在这篇观点文章中，我们强调了肿瘤“糖码”如何改变免疫，并提出靶向糖基可能提供新的治疗机会。
